Gene therapy for spinal muscular atrophy: the Qatari experience
Hossamaldein Gaber Ali(Hamad Medical Corporation), Tawfeg Ben‐Omran(Qatar Airways (Qatar)), Mariam Al‐Mureikhi(Hamad Medical Corporation), Amna Othman(Hamad Medical Corporation), Fatma Al‐Mesaifri(Hamad Medical Corporation), Khaled Elshafey(Hamad Medical Corporation), Hajer Al-Mulla(Hamad Medical Corporation), Karen El‐Akouri(Hamad Medical Corporation), Azhar Othman Al Rawwas(Hamad Medical Corporation), Mahmoud Abeidah(Hamad Medical Corporation), Mariam AlMulla(Hamad Medical Corporation), Khalid Ibrahim, Rehab Ali(Hamad Medical Corporation), Reem Mohamed(Hamad Medical Corporation), Saad Al-Kaabi(Hamad General Hospital), Reem Alsulaiman(Hamad Medical Corporation), Noora Shahbeck(Hamad Medical Corporation), Sara Musa(Hamad Medical Corporation)
Cited by 53
Related Papers
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
|Neuromuscular Disorders|2019|636
Exome Sequencing Links Corticospinal Motor Neuron Disease to Common Neurodegenerative Disorders
|Science|2014|548
Guidelines for the diagnosis and management of cystathionine beta‐synthase deficiency
|Journal of Inherited Metabolic Disease|2016|335